Triplebar, a biotechnology company, has raised USD 20 million in funding, led by Synthesis Capital, with participation from Essential Capital, Stray Dog Capital, iSelect Fund, and others.
The new funds will be used to scale up production and commercialize its portfolio.
Triplebar, founded in 2019, uses a Hyper-Throughput screening platform that integrates hardware, software, biology, and biochemistry for biomanufacturing processes. The company specializes in low-cost animal proteins, cell lines for cultivated meats, and therapeutic drugs.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.